Last reviewed · How we verify
MN-001
At a glance
| Generic name | MN-001 |
|---|---|
| Also known as | tipelukast, Tipelukast |
| Sponsor | MediciNova |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia (PHASE2)
- Safety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary Fibrosis (PHASE2)
- Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects (PHASE2)
- Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MN-001 CI brief — competitive landscape report
- MN-001 updates RSS · CI watch RSS
- MediciNova portfolio CI